Patents by Inventor Nils MYLING-PETERSEN

Nils MYLING-PETERSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240368659
    Abstract: The present disclosure relates to a genetically modified host cell having increased production of one or more vitamin B compounds, wherein the host cell is genetically modified by mutating one or more native polynucleotide constructs for reducing formation of a CRP-cAMP complex in the host cell and/or introducing one or more genetic alterations increasing the degradation and/or non-CRP binding of cAMP in the host cell; whereby the production of the vitamin B compound in the genetically modified host cell is increased compared to a parent host cell.
    Type: Application
    Filed: July 14, 2022
    Publication date: November 7, 2024
    Inventors: Carlos Guillermo ACEVEDO-ROCHA, Daniel Boer BONIFACIO, Benjamin Joseph CADDELL, Hans Jasper GENEE, Luisa Simona GRONENBERG, Kathleen Frances SMART, Nils MYLING-PETERSEN, Bo SALOMONSEN, Gijs VERKLEIJ
  • Patent number: 11851461
    Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 26, 2023
    Assignee: BIOSYNTIA APS
    Inventors: Hans Jasper Genee, Anne Pihl Bali, Nils Myling-Petersen
  • Publication number: 20230192778
    Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
    Type: Application
    Filed: July 12, 2018
    Publication date: June 22, 2023
    Applicant: BIOSYNTIA APS
    Inventors: Hans Jasper GENEE, Anne Pihl BALI, Nils MYLING-PETERSEN
  • Publication number: 20220127311
    Abstract: The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, ?-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 28, 2022
    Applicant: BIOSYNTIA APS
    Inventors: Hans Jasper GENEE, Carlos G. ACEVE-DO-ROCHA, Anne Pihl BALI, Lasse Holm LAURIDSEN, Luisa GRONENBERG, Nils MYLING-PETERSEN